Opportunity ID: 47345

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HD-09-027
Funding Opportunity Title: Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Income Security and Social Services
Category Explanation:
Expected Number of Awards: 3
Assistance Listings: 93.837 — Heart and Vascular Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: May 13, 2009
Last Updated Date:
Original Closing Date for Applications: Nov 10, 2009
Current Closing Date for Applications: Nov 10, 2009
Archive Date: Dec 11, 2009
Estimated Total Program Funding: $3,000,000
Award Ceiling: $1,000,000
Award Floor:

Eligibility

Eligible Applicants: Private institutions of higher education
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs).

Additional Information

Agency Name: National Institutes of Health
Description: Purpose. This funding opportunity announcement (FOA) solicits new (type 1) and competitive renewal (type 2) applications for the support of Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs). Successful applicants will join a network of existing Centers to foster the translation of new scientific findings and technological developments into novel treatments for the muscular dystrophies. Each Center may contain a mixture of basic, translational, or clinical research, as long as efforts are directed toward the steps required for therapeutic development, including therapeutic target identification, characterization, and validation, development of diagnostics and biomarkers to characterize or stratify patient populations, in vitro assay development, animal model development and characterization, candidate therapeutic efficacy screening, preclinical therapeutic optimization and FDA-required activities leading to an investigational new drug (IND) application, clinical infrastructure and studies in support of a clinical trial, patient-oriented natural history studies, and early stage clinical trials for one or more types of muscular dystrophy. Applicants should propose multi-disciplinary and collaborative studies that address one or more gaps in the therapeutic development pipeline for muscular dystrophy. Research problems should require substantial collaborative efforts to solve, and thus are best carried out in a center setting.
Mechanism of Support. This FOA will utilize the U54 Specialized Centers Cooperative Agreement grant mechanism.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-09-027.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

2025-07-10T08:36:36-05:00

Share This Post, Choose Your Platform!

About the Author: